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Venous Thrombo-Embolism (VTE) is a major global health burden. Studies conducted from 4 
continents describe a consistent incidence of approximately 1-2 per 1000 individuals in the 
general population, increasing steeply for those over 70.1,2 The consequences of diagnosis are 
serious; North American data report a 30 day case fatality rate of 10.6% and between 30 to 
50% of survivors will have long term complications.3,4   
Approximately half of all VTE episodes are classified as Hospital Acquired Thrombosis 
(HAT), in that they occur during or shortly after hospitalisation for surgery or acute medical 
illness.5 Many of these cases are potentially preventable through patient education and 
pharmacological thromboprophylaxis. There is a significant body of evidence for the latter; a 
meta-analysis of >15,000 hospitalised trial patients has previously demonstrated a >50% risk 
reduction for VTE with pharmacological thromboprophylaxis, when compared to control.6 In 
many elective surgical settings, routine thromboprophylaxis has become established practice.7,8   
The balance of risk is not so clear in general medical and surgical inpatients requiring 
unscheduled hospitalisation. Pharmacological thromboprophylaxis can lead to adverse events 
in some patients and has a major bleeding rate of approximately 0.4%.8-12 These risks can be 
potentially catastrophic in certain patient groups, such as those with occult bleeding on 
admission, or those undergoing emergency procedures.  As such, the optimal use of 
thromboprophylaxis in this cohort may require individual evaluation of factors relating both to 
the patient and the hospital admission. The best way to conduct this assessment is uncertain.  
Risk Assessment Models (RAMs) have been developed to address the issue, proposing 
individualised and reproducible evaluation of VTE risk. Such models aim to minimise 
unnecessary pharmacological thromboprophylaxis and reduce the associated harm/costs. A 
recent overview of systematic reviews identified 15 available RAMs.13 Although many RAMs 
overlap regarding individual risk factors, there is significant variation between models 
regarding composition and threshold for high VTE risk. By example, application of different 
RAMs to a similar cohort of patients can result in recommendations for pharmacological 
thromboprophylaxis ranging from 32 to 90% of patients (figure 1).14 
There is ongoing uncertainty regarding the optimal method of risk assessment and whether any 
RAM outperforms subjective clinical assessment. In addition, given the international 
BMJ-2020-059910.R2 
 
variability in many RAM components (such as threshold for critical care admission) it is 
unclear whether a validated RAM in one healthcare system will be of equal use in others. 
 
What is the evidence of uncertainty? 
Guidance from the UK National Institute for Health and Care Excellence (NICE) recently 
changed from advocating use of a consensus derived Department of Health (DOH) tool to 
recommending the use of any risk assessment method published by a national body, 
professional network or in a peer reviewed journal.8 Recent American and Australasian 
guidelines also acknowledge the limited evidence both on performance and impact analysis to 
support use of any particular RAM.15-18 Such guidance allows significant variation in practice. 
The comparative performance of different RAMS on clinically relevant outcomes has been 
evaluated in several previous systematic reviews.8,14,19 All conclude a lack of generalisability 
and adequate validation of currently available RAMs. In addition, variability in methods and 
outcome measurement preclude pooled estimates of effectiveness. An expert committee 
informed by systematic review data, recently concluded that ‘none of the tools demonstrated 
sufficiently accurate performance for predicting VTE or bleeding risk based on the evidence.’8   
A recent overview of systematic reviews, last updated in January 2020, identified five widely 
evaluated models which have attempted external validation; the Caprini score, the Padua 
prediction score, the IMPROVE models, the Geneva risk score and Kucher model.13 
Comparative characteristics and individual clinical features for these RAMs and the DOH tool 
(in common use within the UK), are reported in table 1.  
External validation studies reporting performance for the above RAMs are summarised in table 
2. These studies principally report measures of prognostic accuracy by concordance (c) 
statistic, regarding symptomatic VTE by 3-month follow up. In addition, several studies report 
summary estimates of RAM sensitivity (proportion of VTE events accurately predicted by a 
‘high risk’ score at proposed threshold). This evidence shows overall weak prognostic 
performance and variable sensitivity for all RAMs, in keeping with previous systematic review 
findings. There is also limited evidence of safety; only 3 validation studies report estimates of 
major bleeding rates, ranging from 0.7 to 3.4% (table 2).  
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There are significant limitations to this evidence, as highlighted through risk of bias assessment 
(table 2). In particular, observational cohort studies commonly include patients who have 
received thromboprophylaxis at clinical discretion. This will likely reduce the incidence of 
VTE in the at-risk population and may lead to underestimation of RAM accuracy.   
Furthermore, the use of complex RAMs appears to compare unfavorably against simple, 
reproducible criteria. In a secondary analysis of 14,910 patients prospectively recruited to the 
PREVENU study across 25 French Hospitals, Moumneh et al compared the performance of 
age 70 as a single variable against the Padua, Caprini and IMPROVE RAMs for predicting 
VTE risk.20 No significant difference in performance was seen between groups, with the c 
statistic between 0.60 and 0.64 for all, indicating weak prognostic performance.  
Despite these limitations in prognostic accuracy, several RAMs have undergone impact 
analysis and demonstrated improved rates of appropriate pharmacological thromboprophylaxis 
prescribing.14,21-24 One well conducted randomized controlled trial also showed a reduction in 
VTE event rates in patients at high risk.23 This data supports use of any RAM within a clinical 
pathway, to encourage risk assessment and increase appropriate use of thromboprophylaxis. 
 
Is ongoing research likely to provide relevant evidence? 
 
Further external validation research on current RAMs is challenging, given the development 
of national VTE prevention programs and subsequent contractual requirements.25,26 Derivation 
and validation of any new RAM through prospective research would necessitate withholding 
pharmacological prophylaxis from patients identified at risk of VTE, which would be unethical. 
In addition, the widespread use of pharmacological thromboprophylaxis would inevitably 
reduce the number of VTE events in any observational study and confound the association 
between risk factors and VTE events. However, it may be reasonable and ethical to compare 
RAMs to modern clinical gestalt, given the recent international focus on prevention and 
education. It may also be useful to compare alternative RAMs in a cohort of patients identified 
at lower risk for VTE, given the significant uncertainty about which models (and thresholds) 
are optimal.  
We searched EU Clinical Trials Register, ISRCTN Registry and ClinicalTrials.gov and 
identified several actively recruiting studies attempting to prospectively compare existing risk 
models, bleeding risk scores and clinical judgement to improve VTE prevention strategies 
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(table 3). 27,28 The RICO study is a multicenter cluster randomized controlled trial looking to 
compare the performance of thrombosis and bleeding risk assessment using objective RAMs 
(the Padua score and IMPROVE bleeding tool) against clinical judgement. This study is 
currently recruiting and will provide patient level randomized evidence on the clinical 
effectiveness of objective RAMs compared to standard clinical judgement. In addition, a 
further cluster randomized study aims to compare the use of an embedded risk assessment 
process within an electronic healthcare record, using the IMPROVE RAM, to usual medical 
care for VTE prevention.29  
The UK National Institute for Health Research has also recently commissioned a project 
assessing the cost effectiveness of VTE risk assessment tools for hospital inpatients 
(NIHR127454).30 This project will use decision analysis modelling to determine how the cost 
effectiveness of thromboprophylaxis varies for different thresholds of risk from a UK National 
Health Service perspective and which factors contribute most to current uncertainty about the 
optimal threshold for thromboprophylaxis. It will also explore the feasibility of using efficient 
methods to compare alternative RAMs in a large future study.  
Finally, several recent studies have investigated the use of additional biomarkers to improve 
current RAMs. In a retrospective analysis of the MAGELLAN trial, Spyropoulos et al used a 
modified IMPROVE score with the addition of a raised D-dimer (more than twice the upper 
limit of normal) to identify a threefold higher VTE risk in a subgroup of hospitalised acutely 
ill medical patients.31 In a subsequent well conducted systematic review and meta-analysis of 
prognostic factors for VTE in hospitalized medical patients, Darzi et al report moderate 
certainty evidence from 14 studies of a probable association between VTE risk and elevated 
C-reactive protein, D-dimer and fibrinogen levels.32 This recent work has not yet been 
prospectively validated or assessed via implementation studies.  
 
What should we do in light of the uncertainty: 
The revision of recent national guidelines to include multiple options for risk assessment 
suggest that clinicians and patients recognise the limitations of current evidence. However, this 
uncertainty should not necessarily lead to national variation in clinical practice, or outcomes. 
NHS England has used a single recommended risk assessment tool and supporting guidance to 
achieve a consistent reduction in HAT and mortality from VTE.25,26 These results undoubtedly 
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owe as much to the use of a nationally endorsed RAM, coordinated metrics, local quality 
improvement practice and new contractual obligations as they do to original research.  
 
The NHS results also likely arise from use of a RAM which has a low threshold for 
recommending pharmacological thromboprophylaxis.  The recent pandemic has drawn further 
attention to this issue.33,34 UK national guidance has subsequently lowered the bar further in 
this cohort and now recommends pharmacological thromboprophylaxis for all patients 
hospitalized with COVID-19, unless contraindicated by bleeding risk.35 Studies attempting to 
retrospectively validate RAMs in hospitalised patients with COVID-19 continue to be subject 
to significant confounding; the vast majority of patients (90%) receive some form of 
pharmacological thromboprophylaxis.36 
 
As the risk of VTE with hospitalization increases, the requirement for a complex RAM to guide 
individualised decision making is significantly reduced. Decision analytic modelling of the 
benefits, harms and costs of pharmacological thromboprophylaxis suggest it is likely to be cost 
effective from a United States healthcare perspective, for an average medical patient with a 
VTE risk of 1% and a low risk of bleeding.37 Previous estimates suggest the risk of DVT for 
hospitalized medical patients without pharmacological thromboprophylaxis exceeds 10%.7,38 
These data create a compelling rationale to switch the focus of risk assessment from selecting 
‘in’ those at risk, to advocating broader use and using a RAM to identify those patients at low 
risk where pharmacological thromboprophylaxis can potentially be withheld. RAMs may also 
be helpful to identify high risk of bleeding, where potential harm may outweigh any 
benefits.39,40  
 
Current research and international benchmarking initiatives may allow refinement and further 
comparison of prognostic accuracy, reliability and cost effectiveness between RAMs. Until 
such data is available, repeated risk assessment and patient education are crucial. Current 
evidence strongly supports the use of pharmacological thromboprophylaxis in hospitalised 
general medical and surgical patients identified at risk of VTE. In the absence of definitive 
evidence, patients identified at lower risk of VTE using a RAM should be individually 
counselled. In addition, supporting information and clear safety netting throughout hospital 





Box 1 - “What you need to know” 
 Hospital Acquired Thrombosis is responsible for approximately half of all diagnosed 
Venous thromboembolism.  Many cases are potentially preventable, through 
patient education and pharmacological thromboprophylaxis. 
 Different risk assessment models (RAMs) are used in different countries and patient 
groups to help clinicians decide who should be offered pharmacological 
thromboprophylaxis, resulting in wide variations in care and patient experience. 
 It remains uncertain as to which RAM is optimal and whether any complex RAM 
definitively outperforms simple criteria or subjective clinical opinion. 
 
Box 2 – “Search Strategy” 
 Potentially relevant studies were identified through searches of 5 electronic databases 
including MEDLINE (with MEDLINE in-process and Epub ahead of print), 
EMBASE and the Cochrane Library. The search strategy used free text and 
theasaurus terms and combined synonyms relating to the condition (e.g VTE in 
medical inpatients) with risk prediction modelling terms. No language restrictions 
were used. However, as the current review updated three previous systematic reviews, 
searches were limited by date from 2017 (last search date from earlier reviews) to 
March 2021. Searches were supplemented by hand searching the reference lists of all 
relevant studies (including existing systematic reviews); forward citation searching of 
included studies; contacting key experts in the field; and undertaking targeted 
searches of the world wide web using the google search engine.  
 
Box 3 - “How patients were involved in the creation of this article” 
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 Patient representatives from Thrombosis UK and the Sheffield Emergency Care 
Forum have been integral to the funding, development and progress of NIHR127454. 
 The patient author on this article made several suggestions to emphasise the 
importance of repeated patient education, advice on individualised risk reduction and 
safety netting alongside routine clinical risk assessment. 
 
Box 4 – “What patients need to know” 
 Any hospital admission for more than 24h or major surgical procedure can increase 
your risk of developing a blood clot. This increased risk can persist for up to 90 days 
after hospital discharge. 
 Blood clots can be one of the most serious complications associated with an operation 
and/or hospital stay. Many patients can reduce this risk substantially once they are 
properly informed, through increased fluid intake, early mobilisation and regular use 
of preventative therapies. 
 All patients admitted to hospital should undergo a risk assessment for blood clots and 
be offered blood thinning medication if appropriate. This risk assessment can be 
repeated when the clinical situation changes and at the point of hospital discharge. 
Every risk assessment should be accompanied by patient education and supporting 
information to describe the signs and symptoms of blood clots, so that patients know 
when and how to seek help if required. 
 
Box 5 – Recommendations for further research 
Future research should determine whether it is safe to withhold pharmacological 
thromboprophylaxis in hospitalized medical and surgical patients identified at low risk by a 
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validated Risk Assessment Model. Such research could also compare the clinical and cost 
effectiveness of different models  
 P – Hospitalised medical and surgical patients identified at low risk of VTE  
 I – Withholding of routine pharmacological thromboprophylaxis 
 C – Standard care (including pharmacological thromboprophylaxis at the discretion of 
the treating clinician, or as advised by the local RAM).  
 O – Symptomatic VTE events up to 90 days following hospital discharge, including 
objectively diagnosed VTE and/or fatality attributable to VTE. Safety outcomes to 
include major bleeding and clinically relevant non-major bleeding, by international 
definition.41,42  
 
Box 6 - “Education into practice” 
Reflective question: how do you perform a VTE risk assessment for patients you admit to 
hospital and why do you use that particular method? Think about the last time you talked to a 
patient about their VTE risk, to what extent did you counsel them regarding the signs and 
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